Drug or treatment
Siltuximab clinical trials
As of November 12, 2026, Find a Trial lists 5 clinical trials of Siltuximab that are recruiting, at sites in 2 countries (most in United States (4), China (1)). By phase: Phase 2 (3), Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Siltuximab treatment for CRS and ICANS after CAR‑T in multiple myeloma | Phase 2 | Tianjin | Recruiting | Aug 6, 2025 |
| Siltuximab for antibody-mediated rejection after lung transplant | Phase 1 | St Louis, Missouri and 1 other locations | Recruiting | May 25, 2025 |
| Combining Siltuximab with Melphalan for Multiple Myeloma Patients Undergoing Stem Cell Transplant | Phase 2 | Basking Ridge, New Jersey and 6 other locations | Recruiting | Nov 8, 2024 |
| Using siltuximab to prevent severe side effects during cancer treatment | Phase 2 | Columbus, Ohio | Recruiting | Jun 24, 2024 |
| Preventing cytokine release syndrome with siltuximab before epcoritamab treatment | Phase 1 | Cleveland, Ohio | Recruiting | Jun 7, 2024 |
All recruiting trials (5)
-
Siltuximab treatment for CRS and ICANS after CAR‑T in multiple myeloma
We will test whether siltuximab helps adults with multiple myeloma who develop CRS or ICANS after receiving CAR‑T therapy.
-
Siltuximab for antibody-mediated rejection after lung transplant
This study will test whether adding siltuximab, an IL‑6 blocker, to standard treatment is safe and tolerable for adults hospitalized with antibody-mediated rejection after lung transplant.
-
Combining Siltuximab with Melphalan for Multiple Myeloma Patients Undergoing Stem Cell Transplant
This study is testing if combining a new drug called siltuximab with a standard treatment for multiple myeloma can help patients feel better after a stem cell transplant.
-
Using siltuximab to prevent severe side effects during cancer treatment
This study is testing if the drug siltuximab can help prevent severe side effects in cancer patients who are getting immune therapy again.
-
Preventing cytokine release syndrome with siltuximab before epcoritamab treatment
This study is testing if giving siltuximab before treatment with epcoritamab can help prevent serious side effects in people with large B-cell lymphoma or follicular lymphoma.
Quick answers
How many clinical trials of Siltuximab are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (4 trials), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.